Particle Works partners with NTx UK for LNP development
Particle Works, a leading provider of game-changing microfluidic nanoparticle synthesis platforms, is collaborating with NanoVation Therapeutics™ (NTx) UK to reduce the time and costs associated with the screening of novel lipid nanoparticle (LNP) formulations for use in nucleic acid delivery applications.
In this partnership, Oxfordshire-based NTx UK will benefit from Particle Works’ Automated Library Synthesis (ALiS) System, which accelerates LNP formulation development while increasing throughput and precision.
ALiS is a state-of-the-art, high-throughput formulation screening platform that automates the preparation of nanoparticle formulations for various applications, including drug discovery, gene therapy and vaccine development.
Launched in October 2022, the system has already proven to be a valuable asset for scientists seeking an automated, cost-effective and efficient way to screen LNP formulations and mRNA candidates in early-stage development.
ALiS is the latest in a range of automated microfluidic systems designed for use at specific stages of the nanoparticle formulation development process. At each stage, ALiS employs the same re-usable glass microfluidic chips and pumping technology, ensuring the precise production of consistent size and structure particles throughout the development pipeline.
“We are delighted to partner with NanoVation and support the company’s efforts to develop efficient and safe LNP formulations,” explained Lee Jeffries, Managing Director of Particle Works.
“ALiS is designed for the automated and high-throughput screening of nanoparticle formulations, and we believe it can play a critical role in helping NanoVation to accelerate the development of its future projects.
“Particle Works is committed to providing innovative solutions that can drive breakthroughs in research and development, and we believe this collaboration is a great step in that direction. We look forward to holding future workshops with the NanoVation team.”
“We are very excited to partner with Particle Works and to use its ALiS platform in our LNP research,” said Arpan Desai, Managing Director of NTx UK.
“There is nothing on the market quite like it, and we believe it could be a game changer for the high-throughput screening of our LNP formulations. ALiS’ ability to automate the preparation of nanoparticle formulations is unique, and we are excited to see the impact it will have on our work.”
About Particle Works
Particle Works combines a strong heritage in engineering with nanoparticle knowledge, microfluidic expertise and in-house microfluidic chip fabrication. They design and manufacture state-of-the-art particle engineering platforms, paving the way to particle perfection.
Their technology is used in a wide range of applications, including the production of
nanoparticle-based vaccines, medicines, and therapeutics. Their platforms enable scientists to formulate particles faster, ensuring they are ready for their next breakthrough and the scale up of discoveries.
Particle Works is part of Blacktrace Holdings Limited – a world leader in Productizing Science™ – and is based in Royston (near Cambridge) UK.
About NanoVation Therapeutics™ (NTx)
NanoVation Therapeutics (NTx) is a gene therapy company developing next-generation platform technologies based on lipid nanoparticles for the safe and efficient delivery of nucleic acids. NTx’s one-stop-shop IP portfolio is utilized to tune formulations to specific applications as well as a variety of tissues.
Focused on improving the lives of patients by empowering genetic medicines that prevent, treat, and cure diseases, NTx is a trusted partner for companies globally delivering tomorrow’s genetic medicines, TODAY.